cultivate(MD) Capital Funds Announces Lead Participation in Portfolio Company Embody’s $10.4 million Series C Funding Round

cultivate(MD) Capital Funds Announces Lead Participation in Portfolio Company Embody’s $10.4 million Series C Funding Round

  • Funds
  • September 20, 2022
  • No Comment
  • 4

Funds to Support Commercial Expansion and Post-Market Clinical Studies of Tapestry® for tendon and ligament injuries.

GRAND RAPIDS, Mich., Sept. 20, 2022 /PRNewswire/ — cultivate(MD) Capital Funds LP, funds that are focused on investments into early-stage healthcare companies with innovative technologies, announced today that one of their portfolio companies, Norfolk, VA based Embody, Inc. announced a $10.4 million Series C financing. Embody, Inc., is a privately-held medical device company focused on soft tissue healing. 

Led by the cultivate(MD) Accelerator Capital Fund, the funding will enable Embody to expand its world-class operations, post-market clinical studies of the recently launched Tapestry RC System for rotator cuff and prepare for the commercial launch of ActivBraid™ high-strength collagen-based suture technology in 2023. 

“This financing represents a notable step in the continued growth of Embody” said Jeff Conroy, Embody’s Founder and Chief Executive Officer.  “We are thrilled to have the continued support of our highly seasoned investor base, further illustrating the opportunity and need of our soft tissue healing technology portfolio.”

Embody has pioneered the next generation regenerative platform with novel collagen-based bio-fabrication techniques and products for the fast-growing sports medicine market, including rotator cuff repair, foot & ankle, and knee.

“Embody’s collagen technologies have the potential to redefine the standard of care and approaches to the treatment of tendon and ligament injuries,” noted cultivate(MD) venture funds Executive Director, R. Sean Churchill, MD, MBA “We are proud to partner with Embody and believe the technology and team are well positioned to be a leader in the sports medicine market space.”

About Embody: Embody, the soft tissue healing company, is pioneering the next generation regenerative platform with novel collagen-based bio-fabrication techniques and products for the fast-growing sports medicine market.  The global market for sports medicine products is expected to reach $11 billion by 2023.  Embody’s products focus on the most pressing patient needs: the repair of serious tendon and ligament injuries and are developed in close collaboration with some of the most advanced clinical thought leaders.  Founded in 2014 and funded more than $23 million in DARPA & DOD funding, the company is developing unique biomaterials with an initial focus on orthopedic applications including foot & ankle, rotator cuff and knee ligament.

About cultivate(MD) Capital Funds: As a medical device venture capital fund, cultivate(MD) is dedicated to bringing emerging health care innovations to market, with a special focus on medical device and orthopedic technologies. cultivate(MD) is focused on investing in early stage healthcare companies with innovative technologies that have demonstrated evidence of effectiveness.  For more information, visit:  https://genesisinnovationgroup.com/

This press release does not constitute an offer to sell or solicitation of an offer to buy any securities in any offering of securities.  There will not be any sale of any securities in any state or jurisdiction in which such offering, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forwarding-Looking Statements`

Certain statements in this press release constitute forward-looking statements. When used in this press release, the words “will,” “anticipate,” and similar expressions or the negatives thereof are generally intended to identify forward-looking statements. Such forward-looking statements, including the intended actions and performance objectives of the fund, its general partner, cultivate(MD), or any cultivate(MD) portfolio company referenced herein, involve known and unknown risks, uncertainties, and other important factors that could cause the actual results, performance, or achievements of the general partner, or any cultivate(MD) fund or portfolio company to differ materially from any future results, performance, or achievements expressed or implied by such forward-looking statements. No representation or warranty is made as to future performance or such forward-looking statements. All forward-looking statements in this press release speak only as of the date hereof.  The fund, its general partner, and cultivate(MD) expressly disclaim any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement contained herein to reflect any change in its expectation with regard thereto or any change in events, conditions, or circumstances on which any such statement is based. 

SOURCE cultivate(MD) Capital Funds

Source link

Related post

How the EU’s new energy plans impact Southeast Asia

How the EU’s new energy plans impact Southeast Asia

Amid an ongoing energy, European countries have turned to Southeast Asia’s coal and liquefied natural gas (LNG) producers to help offset…
Private equity makes million-dollar investment in UK pet treat manufacturer

Private equity makes million-dollar investment in UK pet treat…

YORKSHIRE, UNITED KINGDOM — Private equity Traditum announced its £1.75 million ($1.9 million USD) investment in Sniffers Pet Care on Sept.…
This week in tax: EU concerns over pillar two vote

This week in tax: EU concerns over pillar two…

European Commissioner for the Economy Paolo Gentiloni elaborated on tax reform in Parliament this week, including plans to enact the OECD’s…

Leave a Reply

Your email address will not be published.